Pipeline

Pipeline

Pipeline

Targeting Adaptive Stress and Innate Immunity

We have developed a differentiated pipeline of therapy candidates that address dynamic drivers of treatment resistance, cancer relapse and metastasis.  We are actively developing our therapeutic candidates in clinical trials for large indications of unmet need for patients.

Our Pipeline


Program
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Innate & Adaptive Immune Modulator
Target Click Odetiglucan
(Dectin-1)
Liver Metastasis
Odetiglucan
monoTx
Pancreatic Cancer
Odetiglucan
monoTx

Odetiglucan (Imprime PGG) is our systemically administered innate and adaptive immune modulator therapeutic candidate.   We plan to initiate a Phase 1b clinical trial in combination with a CD40 agonistic antibody in pancreatic cancer and a Phase 2 clinical trial in combination with an immune checkpoint inhibitor in adults with colorectal cancer liver metastases in 2023.

Adaptive Stress Modulators
Target Click HC-5404
(PERK)
Advanced RCC, Gastric Cancer & Other Advanced Solid Tumors
HC-5404 monoTx

HC-5404, our first adaptive stress product candidate, is a differentiated highly selective, orally bioavailable inhibitor of a key stress response protein kinase, PERK. We are developing HC-5404 for stress driven tumors, including von Hippel-Lindau, or VHL, mutated RCC, gastric cancer and other solid tumors.

Target Click HC-7366
(GCN2)
Advanced HNSCC, CRC, Bladder Cancer & Other Advanced Solid Tumors
HC-7366 monoTx

HC-7366, our second adaptive stress product candidate, is a differentiated selective, orally bioavailable modulator of another key stress response protein kinase, GCN2.  We are developing HC-7366 for the treatment of advanced solid tumors and are exploring the potential of HC-7366 in hematological malignancies.



Targeting critical adaptive stress mitigating pathways

Modulating the immune system’s defense mechanisms